Merck bets big on oral PCSK9 inhibitor, putting 6-year outcome study at heart of phase 3 program

Merck & Co. is betting big on its oral PCSK9 inhibitor. Buoyed by midphase results, the Big Pharma has kicked off a clutch of late-stage studies including a cardiovascular outcomes trial that will follow patients for around six years.